Place de l'acarbose dans le traitement du diabete sucre.

Scheen, André

No full text

Article (Scientific journals)

Place de l'acarbose dans le traitement du diabete sucre.

Scheen, André

1998 • In Diabetes and Metabolism, 24 (4), p. 385-90

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/12899

PubMed
9805654

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Acarbose; Blood Glucose/metabolism; Clinical Protocols; Diabetes Mellitus, Type 2/blood/diet therapy/drug therapy; Diabetic Diet; Humans; Hypoglycemic Agents/therapeutic use; Trisaccharides/therapeutic use

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Place de l'acarbose dans le traitement du diabete sucre.

Alternative titles :

[fr] Role of acarbose in the treatment of diabetes mellitus

Publication date :

1998

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Masson, Moulineaux Cedex 9, France

Volume :

Issue :

Pages :

385-90

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 May 2009

Statistics

Number of views

112 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, 1183-1197.
Scheen AJ, Paquot N, Lefèbvre PJ. Etiologie et physiopathologie du diabète non insulinodépendant. Encyclopédie Médico-Chirurgicale (Paris-France). Endocrinologie-Nutrition, 1995, 10, 366-D-10: 7p.
Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet, 1995, 343, 95-100.
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s : achievements and future developments. Drugs, 1997, 54, 355-368.
Alberti KGMM, Gries FA, Jervell J, Krans HMJ for the European NIDDM Policy Group. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM) : an update. Diabetic Med, 1994, 11, 899-909.
American Diabetes Association. Consensus Statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care, 1995, 18, 1510-1518.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic drugs : a guide to selection. Drugs, 1998, 55, 225-236.
Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am, 1997, 26, 659-677.
Rothwell PM. Can overall results of clinical trials be applied to all patients ? Lancet, 1995, 345, 1616-1619.
Creutzfeldt W, ed Proceedings of the First International Symposium on Acarbose. Acarbose. Effects on carbohydrate and fat metabolism. Amsterdam : Excerpta Medica, 1982.
Creutzfeldt W, ed. Proceedings of the Second International Symposium on Acarbose. Acarbose for the treatment of diabetes mellitus. Berlin : Springer Verlag, 1988.
Lefèbvre PJ, Standl E, eds. New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors. Berlin, New York : de Gruyter, 1992.
Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs, 1988, 35, 214-243.
Balfour JA, McTavish D. Acarbose - an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs, 1993, 46, 1025-1054.
Toeller M. Inhibiteurs de l'α-glucosidase. In : Journées Annuelles de Diabétologie de l'Hôtel-Dieu, Flammarion Médecine-Sciences, Paris, 1991, 203-212.
Chiasson J-L, Gerich JE (eds). α-glucosidase inhibitors : a new therapeutic option in diabetes mellitus. Drugs, 1992, 44 (Suppl. 3), 1-65.
Nieuwenhuijzen Kruseman AC, Sels JPJE, Wolffenbuttel BHR, editors, α-glucosidase inhibitors in diabetes. Eur J Clin Invest, 1994, 24 (Suppl. 3), 1-54.
Kuhlmann J, Puls W (eds). Oral antidiabetics. Handbook of Experimental Pharmacology. Berlin : Springer Verlag, 1996.
Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet, 1996, 30, 94-106.
Meng-Hee Tan. α-glucosidase inhibitors in the treatment of diabetes. Curr Opin Endocrinol Diab, 1997, 4, 48-55.
Spengler M, Cagatay M. The use of acarbose in the primary-care setting : evaluation of efficacy and tolerability of acarbose by post-marketing surveillance study. Clin Invest Med, 1995, 18, 325-331.
Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients (Abstract). Diabetologia, 1996, 39 (Suppl 1), A44.
Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus : a critical review of controlled trials. Diab Metab, 1998, 24, 225-236.
Baron A, Neumann C, on Behalf of the PROTECT Study Group. PROTECT interim results : a large multicenter study of patients with type II diabetes. Clin Ther, 1997, 19, 282-295.
Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus : a multicenter controlled clinical trial. Ann Intern Med, 1994, 121, 928-935.
Rodier M, Richard JL, Monnier L, Mirouze J. Effect of long term Acarbose (Bay-g-5421) therapy on metabolic control of non-insulin-dependent (type II) diabetes mellitus. Diab Metab, 1988, 14, 12-14.
Gérard J, Luyckx A, Lefèbvre P. Improvement of metabolic control in insulin-dependent diabetics treated with the α-glucosidase inhibitor acarbose for two months. Diabetologia, 1981, 21, 446-451.
Tattersall R. Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes. Diab Med, 1993, 10, 688-693.
Scheen AJ, Lefèbvre PJ. Le diabète instable : définition, causes et conséquences. In : Journées de Diabétologie de l'Hôtel-Dieu 1995, Flammarion Médecine-Sciences, Paris, 229-241.
Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of α-glucosidase inhibitors on lipids in NIDDM with moderate hyperlipidaemia. Eur J Clin Invest, 1994, 24 (Suppl. 3), 45-49.
Zimmerman BR. Preventing long-term complications. Implications for combination therapy with acarbose. Drugs, 1992, 44 (Suppl. 3), 54-60.
Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Safety, 1994, 11, 432-444.
Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs, 1996, 51, 931-941.
Berger M, Köbberling J, Windeler J. Appraisal of effectiveness and potential therapeutic benefit of acarbose : a non-consensus conference. Diabetologia, 1996, 39, 873-874.
Anonymous. Acarbose for diabetes mellitus. Med Lett Drugs Ther, 1996, 38, 9-10.
Lerman I, Gomez Pérez FJ, Aguilar-Salinas CA, Rull Rodrigo JA. Acarbose : in search for its real indications in current medical practice. Diabetes Care, 1996, 19, 94-95.